Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy (TIGHT)

15. november 2026 oppdatert av: Andrea Galli, IRCCS San Raffaele

Impact of Compressive Dressing on the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Multicenter Retrospective Observational Study

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

Studietype

Observasjonsmessig

Registrering (Antatt)

950

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Bergamo, Italia
        • Rekruttering
        • ASST Papa Giovanni XXIII
        • Ta kontakt med:
      • Bologna, Italia
        • Rekruttering
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • Ta kontakt med:
          • Edoardo Serafini, Medical Degree
          • Telefonnummer: +39 051 2145263
      • Bologna, Italia
        • Rekruttering
        • Ospedale Maggiore Carlo Alberto Pizzardi
        • Ta kontakt med:
      • Bolzano, Italia
        • Rekruttering
        • Ospedale Centrale di Bolzano
        • Ta kontakt med:
          • Luca Calabrese, medical degree
          • Telefonnummer: +39 0471 438641
          • E-post: orlbz@sabes.it
      • Brescia, Italia
        • Rekruttering
        • ASST degli Spedali Civili di Brescia
        • Ta kontakt med:
      • Candiolo, Italia
        • Rekruttering
        • IRCCS Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
        • Ta kontakt med:
      • Cesena, Italia
        • Rekruttering
        • Ospedale M. Bufalini
        • Ta kontakt med:
      • Florence, Italia
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Careggi
        • Ta kontakt med:
          • Giandomenico Maggiore, Medical Degree
          • Telefonnummer: +39 055 7942000
      • Forlì, Italia
        • Rekruttering
        • Ospedale G.B. Morgagni - L. Pierantoni
        • Ta kontakt med:
      • Milan, Italia
      • Milan, Italia
        • Rekruttering
        • Ospedale San Raffaele
        • Ta kontakt med:
        • Ta kontakt med:
      • Modena, Italia
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Policlinico di Modena
        • Ta kontakt med:
      • Naples, Italia
      • Padova, Italia
        • Rekruttering
        • Azienda Ospedale-Università di Padova
        • Ta kontakt med:
      • Pavia, Italia
        • Rekruttering
        • Fondazione IRCCS Policlinico San Matteo
        • Ta kontakt med:
      • Pescara, Italia
      • Ravenna, Italia
        • Rekruttering
        • Ospedale Santa Maria delle Croci
        • Ta kontakt med:
      • Reggio Emilia, Italia
        • Rekruttering
        • Arcispedale Santa Maria Nuova
        • Ta kontakt med:
      • Rimini, Italia
      • Roma, Italia
      • Roma, Italia
      • Roma, Italia
      • Torino, Italia
        • Rekruttering
        • AOU Città della Salute e della Scienza (Molinette)
        • Ta kontakt med:
      • Trieste, Italia
        • Rekruttering
        • Ospedale di Cattinara
        • Ta kontakt med:
          • Giancarlo Tirelli, Medical Degree
          • Telefonnummer: +39 040 3994933
          • E-post: tirellig@units.it
      • Verona, Italia
        • Rekruttering
        • Azienda Ospedaliera Universitaria Integrata di Verona
        • Ta kontakt med:
      • Vittorio Veneto, Italia
        • Rekruttering
        • Ospedale di Vittorio Veneto - ULSS 2 Marca Trevigiana
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

N/A

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

Beskrivelse

Inclusion Criteria:

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • Informed consent to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Compressive dressing (Group A)

Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

No compressive dressing (Group B)

Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of pharyngocutaneous fistula
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of pharyngocutaneous fistula by duration of compressive dressing
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients whose fistula resolved, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
Tidsramme: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Edoardo Serafini, Medical Degree, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. mai 2025

Primær fullføring (Antatt)

5. januar 2027

Studiet fullført (Antatt)

31. mars 2027

Datoer for studieregistrering

Først innsendt

15. november 2026

Først innsendt som oppfylte QC-kriteriene

15. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 162/2025/Oss/AOUBo

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

IPD-delingstidsramme

After publication of the study results in a peer-reviewed journal.

Tilgangskriterier for IPD-deling

Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .